Mitochondrial electron transport is the cellular target of the oncology drug elesclomol
about
Integration of Mitochondrial Targeting for Molecular Cancer TherapeuticsTreatment Strategies that Enhance the Efficacy and Selectivity of Mitochondria-Targeted Anticancer AgentsIncreasing Superoxide Production and the Labile Iron Pool in Tumor Cells may Sensitize Them to Extracellular AscorbateMitochondrial respiration--an important therapeutic target in melanomaFunctional toxicology: tools to advance the future of toxicity testing.A functional screen for copper homeostasis genes identifies a pharmacologically tractable cellular system.Inhibition of PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells.Mapping the cellular response to small molecules using chemogenomic fitness signatures.Loss of APD1 in yeast confers hydroxyurea sensitivity suppressed by Yap1p transcription factorA genome-wide screen identifies yeast genes required for tolerance to technical toxaphene, an organochlorinated pesticide mixturePharmacological activity of metal binding agents that alter copper bioavailability.Evolutionary and Biochemical Aspects of Chemical Stress Resistance in Saccharomyces cerevisiae.Ovarian cancer: emerging molecular-targeted therapies.Targeting metabolic flexibility by simultaneously inhibiting respiratory complex I and lactate generation retards melanoma progression.Clawing back: broadening the notion of metal chelators in medicineFunctional genomics indicates yeast requires Golgi/ER transport, chromatin remodeling, and DNA repair for low dose DMSO tolerancePrediction of gene phenotypes based on GO and KEGG pathway enrichment scores.ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia.Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf-mutant inhibitor.Another facet to the anticancer response to lamellarin D: induction of cellular senescence through inhibition of topoisomerase I and intracellular Ros productionLoss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells.What is the role of chemotherapy in the treatment of melanoma?NetwoRx: connecting drugs to networks and phenotypes in Saccharomyces cerevisiae.Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells.Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations.Small molecule-induced mitochondrial disruption directs prostate cancer inhibition via UPR signalingImportance of glycolysis and oxidative phosphorylation in advanced melanoma.Evolutionary analysis of multidrug resistance genes in fungi - impact of gene duplication and family conservation.Silencing of NAC1 Expression Induces Cancer Cells Oxidative Stress in Hypoxia and Potentiates the Therapeutic Activity of Elesclomol.A novel calcineurin-independent activity of cyclosporin A in Saccharomyces cerevisiaeA single nucleotide polymorphism in the Plasmodium falciparum atg18 gene associates with artemisinin resistance and confers enhanced parasite survival under nutrient deprivation
P2860
Q26771751-39EA3A68-DA3B-4483-9F13-919A33A4B3EAQ26800890-3181C34F-8301-4410-A3A8-B9DFD0FC4C17Q27021794-A2748A7D-1DB3-4564-A4DF-C62AAA07D8C3Q28482377-DCAC98BA-BCBF-4934-8142-053E4F423023Q33595247-700946AD-464E-481C-ADC4-EB1A40027FB5Q33622307-C0359EFC-133C-4F60-BA57-E85E9504253FQ34466148-A982CD2A-64B8-403B-8BF3-47FA855C4716Q34626429-5DEBF6CF-0F72-4CE1-9264-F445AC6EA8F1Q34983831-F9A93A1D-0D3D-49DD-B3D7-C76B5AD3427EQ35049516-B4F34E52-0DDC-4577-8CE7-E938D724089DQ35587484-717C150F-ADF7-4A07-A1B0-56AAA2896529Q35861568-A6C10514-FF36-4D29-95AB-19A273258081Q36092472-DFF711BB-8DB2-4B6F-9D63-76F89E99C3B4Q36545721-8EB54AEF-2DB6-4DF0-9D31-780493BC0AEBQ36791445-439C7126-3DD4-4DBD-B79E-E31981DB529FQ37090035-2780F799-7FC1-432B-8923-0C3A89760C4FQ37338200-417EE898-87B8-4EDA-971D-97290CA2CF23Q37379680-A2AAAC19-FC9A-46DB-8DB6-AB0061EB7522Q37420174-21734434-8FBD-40C2-B8FF-591741764EAEQ37621112-1CEBBAE8-47BA-423B-9CFA-B7A71E1008C6Q37636724-632E3202-6D43-4E4A-93AA-A9632158FC03Q38193716-252145E1-79DE-4C26-91A5-C9D42505D5BFQ38460358-E06FCECA-56CC-4304-881D-1B6DDE687671Q38747870-C7CB01B8-0B9C-41A3-A6B8-84B29E867718Q38934404-1BCC84C4-1157-4897-8944-571251E80164Q39117495-64644299-A42B-4066-AA8B-FB26E28565CAQ39264242-06A310BA-341B-4F5D-ACE2-2C5229B285D6Q45391161-AB3A48DC-30CF-4DE2-9221-6671B2BA2EC0Q46256712-A8A83052-033C-4A5A-9FF6-98487B4BD2F3Q57269182-ACC258FC-A890-42BC-8EA6-8F7CB321EE3DQ58115287-CF391C8B-DDDA-4640-A86E-2FE5ED520F9E
P2860
Mitochondrial electron transport is the cellular target of the oncology drug elesclomol
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Mitochondrial electron transport is the cellular target of the oncology drug elesclomol
@ast
Mitochondrial electron transport is the cellular target of the oncology drug elesclomol
@en
Mitochondrial electron transport is the cellular target of the oncology drug elesclomol
@nl
type
label
Mitochondrial electron transport is the cellular target of the oncology drug elesclomol
@ast
Mitochondrial electron transport is the cellular target of the oncology drug elesclomol
@en
Mitochondrial electron transport is the cellular target of the oncology drug elesclomol
@nl
prefLabel
Mitochondrial electron transport is the cellular target of the oncology drug elesclomol
@ast
Mitochondrial electron transport is the cellular target of the oncology drug elesclomol
@en
Mitochondrial electron transport is the cellular target of the oncology drug elesclomol
@nl
P2093
P2860
P50
P3181
P1433
P1476
Mitochondrial electron transport is the cellular target of the oncology drug elesclomol
@en
P2093
Aurelie Jonneaux
David A Proia
Jane Kepros
Kahlin Cheung-Ong
Patricia E Rao
Ronald K Blackman
Yumiko Wada
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0029798
P407
P577
2012-01-01T00:00:00Z